Coagulation cascade serine proteases and cofactors (Coagulation factors)

The coagulation cascade serine proteases and cofactors are a group of plasma proteins that mediate the complex process of blood clot formation through a series of proteolytic activations [1.1.1, 1.1.3]. This system includes serine proteases such as Prothrombin (Factor II), Factor VII, Factor IX, Factor X, Factor XI, and Factor XII, along with essential non-enzymatic cofactors like Factor V and Factor VIII [1.1.2, 1.1.3]. These proteins function in a biochemical amplification pathway where each activated protease catalyzes the activation of the next zymogen, ultimately leading to the generation of thrombin and the conversion of fibrinogen into a stable fibrin mesh [1.3.3, 1.3.4]. Dysregulation of these factors is central to cardiovascular diseases, including venous thromboembolism, atrial fibrillation, and stroke, as well as bleeding disorders like hemophilia [1.1.3, 1.3.1]. Therapeutic agents targeting this cascade include direct inhibitors of Factor Xa (e.g., Rivaroxaban) and Thrombin (e.g., Dabigatran), as well as indirect anticoagulants like Heparin and Vitamin K antagonists like Warfarin [1.2.1, 1.2.4]. While these drugs are critical for preventing thrombosis, they carry significant safety concerns, primarily the risk of major hemorrhage [1.2.1, 1.2.3].

Other names

Blood clotting factorsProcoagulantsCoagulation factorsHemostatic factorsClotting cascade proteins

Anticoagulants inhibit the cascade by directly blocking the active sites of serine proteases (e.g., Thrombin, Factor Xa), indirectly enhancing endogenous inhibitors like Antithrombin, or interfering with the synthesis of vitamin K-dependent factors [1.1.4, 1.2.4, 1.3.3]. Procoagulant therapies replace deficient factors or bypass inhibitors to restore hemostasis [1.2.3].